Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
CLOTRIMAZOLE (UNII: G07GZ97H65) (CLOTRIMAZOLE - UNII:G07GZ97H65), BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)
NuCare Pharmaceuticals,Inc.
TOPICAL
PRESCRIPTION DRUG
Clotrimazole and betamethasone dipropionate cream USP is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. None. Teratogenic effects, Pregnancy Category C There are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. Therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. Corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. Studies in pregnant rats with intravaginal doses up
Clotrimazole and betamethasone dipropionate cream USP, 1%/0.05% (base) is supplied as: NDC 68071-4134-4 Box of 45 g. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Rx only
Abbreviated New Drug Application
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE- CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM NUCARE PHARMACEUTICALS,INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM. CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM USP, 1%/0.05% (BASE), FOR TOPICAL USE INITIAL U.S. APPROVAL: 1984 INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream USP contains a combination of clotrimazole USP, an azole antifungal, and betamethasone dipropionate USP, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to _Epidermophyton floccosum, Trichophyton mentagrophytes,_ and _Trichophyton rubrum_ in patients 17 years and older. ( 1) DOSAGE AND ADMINISTRATION • Tinea pedis: Apply a thin film to the affected skin areas twice a day for 2 weeks. ( 2) • Tinea cruris and tinea corporis: Apply a thin film to the affected skin area twice a day for 1 week. ( 2) • Clotrimazole and betamethasone dipropionate cream should not be used longer than 2 weeks in the treatment of tinea corporis or tinea cruris, and longer than 4 weeks in the treatment of tinea pedis. ( 2) • Do not use with occlusive dressings unless directed by a physician. ( 2) • Not for ophthalmic, oral or intravaginal use. ( 2) DOSAGE FORMS AND STRENGTHS Cream, 1%/0.05% ( 3) Each gram of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) contains 10 mg of clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) ( 3) CONTRAINDICATIONS None. ( 4) WARNINGS AND PRECAUTIONS • Clotrimazole and betamethasone dipropionate cream can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of the treatment. Risk factor(s) are: use of hi Les hele dokumentet